Literature DB >> 25742894

Advanced thymic cancer treated with carboplatin and paclitaxel in a patient undergoing hemodialysis.

Satoru Miura1, Hiroshi Kagamu, Takehito Sakai, Koichiro Nozaki, Katsuaki Asakawa, Hiroshi Moro, Masaaki Okajima, Satoshi Watanabe, Suguru Yamamoto, Noriaki Iino, Shin Goto, Junichiro James Kazama, Hirohisa Yoshizawa, Ichiei Narita.   

Abstract

A 53-year-old man with an asymptomatic anterior mediastinal tumor undergoing hemodialysis was referred to our institution. He was diagnosed with thymic basaloid carcinoma based on the findings of a chest tomography-guided biopsy and successfully treated with carboplatin (300 mg/m(2)/day) and paclitaxel (200 mg/m(2)/day) on day 1 for six three-week cycles. To our knowledge, this is the first report regarding the efficiency of a carboplatin dose-definition method based on the body surface area with paclitaxel in a hemodialysis patient. This report may therefore be useful for treating hemodialysis patients who are candidates for carboplatin and paclitaxel therapy.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25742894     DOI: 10.2169/internalmedicine.54.3484

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  1 in total

1.  Two-year disease remission of an unresectable basaloid thymic carcinoma with second line chemotherapy drugs: report of a case.

Authors:  Agustín Buero; Silvia Quadrelli; Leonardo German Pankl; Felix Vigovich
Journal:  Pan Afr Med J       Date:  2019-05-24
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.